<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">89467</article-id><article-id pub-id-type="doi">10.35693/2500-1388-2022-7-1-50-53</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Oncology and radiotherapy</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Assessing the risk of ovarian cancer relapse with special software: a clinical case</article-title><trans-title-group xml:lang="ru"><trans-title>Пример оценки индекса риска рецидивирования рака яичников при помощи компьютерной программы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5115-6388</contrib-id><name-alternatives><name xml:lang="en"><surname>Gataullin</surname><given-names>Ilgiz G.</given-names></name><name xml:lang="ru"><surname>Гатауллин</surname><given-names>Ильгиз Габдуллович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Professor of the Department of Oncology, radiology and palliative care</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры онкологии, радиологии и паллиативной медицины</p></bio><email>ilgizg@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7048-4125</contrib-id><name-alternatives><name xml:lang="en"><surname>Savinova</surname><given-names>Aigul R.</given-names></name><name xml:lang="ru"><surname>Савинова</surname><given-names>Айгуль Рафисовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>oncologist of the Department of Oncology №10</p></bio><bio xml:lang="ru"><p>врач-онколог онкологического отделения №10</p></bio><email>aigulkazan@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan State Medical Academy</institution></aff><aff><institution xml:lang="ru">Казанская государственная медицинская академия – филиал ФГБОУ ДПО РМАНПО Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Tatarstan Regional Clinical Cancer Center</institution></aff><aff><institution xml:lang="ru">Республиканский клинический онкологический диспансер Минздрава Республики Татарстан</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2022</year></pub-date><volume>7</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>50</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2021-11-30"><day>30</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-23"><day>23</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Gataullin I.G., Savinova A.R.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Гатауллин И.Г., Савинова А.Р.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Gataullin I.G., Savinova A.R.</copyright-holder><copyright-holder xml:lang="ru">Гатауллин И.Г., Савинова А.Р.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/89467">https://innoscience.ru/2500-1388/article/view/89467</self-uri><abstract xml:lang="en"><p>The article presents a clinical observation of a patient with ovarian cancer, stage IIIA according to FIGO (International Federation of Obstetrics and Gynecology), after completing the first-line combination therapy for whom we determined the risk of recurrence using a special software.</p> <p>The early prediction of the ovarian cancer relapse was based on calculated ARRNO index (Assessment of Risk of Relapse of Neoplasm of Ovary). As initial data the following characteristics were inserted into the program: disease stage according to FIGO, tumor differentiation stage (Grade), hystotype, state of residual tissue on ultrasound examination after the treatment, levels of СА-125 before the treatment, levels of НЕ-4 after the treatment. The ARRNO software calculated the individual risk of relapse in 3 limits: low (0 - 0,39), moderate (0,40 - 0,85) and high (0,86 - 1,0).</p> <p><bold>Conclusion.</bold> The special software for assessing the risk of relapse of ovarian neoplasm proved to be simple to operate and allowed to predict the relapse with high probability.</p></abstract><trans-abstract xml:lang="ru"><p>В статье приведено клиническое наблюдение определения риска рецидивирования у пациентки с раком яичников IIIA стадии по FIGO после завершения первой линии комбинированной терапии с использованием разработанной нами компьютерной программы.</p> <p>Была произведена оценка доклинической манифестации рецидива рака яичников путем вычисления индекса ИРРРЯ (индивидуальный риск рецидива рака яичников). В качестве исходных параметров в программу вводятся такие показатели, как стадия заболевания по FIGO (International Federation of Obstetrics and Gynecology), степень дифференцировки опухоли (Grade), гистотип, наличие или отсутствие остаточной опухоли при УЗИ после завершения лечения, значение уровня онкомаркера СА-125 до начала лечения, значение уровня онкомаркера НЕ-4 после окончания лечения. Программа рассчитывает индивидуальный риск рецидивирования в 3 промежутках значений: низкий (0 – 0,39), умеренный (0,40 – 0,85) и высокий (0,86 – 1,0).</p> <p><bold>Заключение. </bold>Компьютерная программа для оценки индивидуального риска рецидивирования рака яичников является простой в использовании и с высокой точностью прогнозирует вероятность рецидивирования.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ovarian cancer</kwd><kwd>risk of relapse assessment</kwd><kwd>software</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак яичников</kwd><kwd>оценка риска рецидивирования</kwd><kwd>программа оценки риска рецидивирования</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Liest AL, Omran AS, Mikiver R, et al. RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study. Acta Obstetricia et Gynecologica Scandinavica. 2019;1(98):24–33. doi: 10.1111/aogs.13462</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ionescu CA, Matei A, Navolan D, et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (Baltimore). 2018;97(31):e11762. doi: 10.1097/MD.0000000000011762</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Salim E, Zubairi AM, Danish SH, Ali U. Diagnostic Accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) in Post-Menopausal Patients with Ovarian Mass. J Coll Physicians Surg Pak. 2018;28(6):440–444. doi: 10.29271/jcpsp.2018.06.44</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Calester B, Van Hoorde K, Froyman W, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts Views Vis Obgyn. 2015;7(1):32–41. PMID: 25897370</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Schneider S, Armbrust R, Spies C, et al. Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review. Arch Gynecol Obstet. 2020;301(2):315–326. doi: 10.1007/s00404-019-05321-7</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Devlin MJ, Ledermann JA, Lockley M, et al. 975P Clear cell ovarian cancer (CCOC): Predicting risk of relapse (ROR). Annals of Oncology. 2018;29(8)։7–12. doi: 10.1093/annonc/mdy285.182</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Narasimhulu DM, Kumar A, Weaver AL, et al. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2019;155(1):58–62. doi: 10.1016/j.ygyno.2019.08.004</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Savinova AR, Gataullin IG, Shakirov RR. Method of assessment of the risk of relapse of ovarian cancer. Patent of Russian Federation No. 2251692, published on 10.05.2015, Bulletin No. 13. (In Russ.). [Савинова А.Р., Гатауллин И.Г., Шакиров Р.Р. Способ оценки риска рецидивирования рака яичников. Патент Российской Федерации № 2251692, опубликованный 10.05.2015, бюллетень № 13].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Savinova AR, Gataullin IG. Relapse of ovarian neoplasm: individual risk assessment algorithm. Science and Innovations in Medicine. 2019;4(3):65–68. (In Russ.). [Савинова А.Р., Гатауллин И.Г. Алгоритм оценки индивидуального риска рецидивирования рака яичников. Наука и инновации в медицине. 2019;4(3):65–68]. doi: 10.35693/2500-1388-2019-4-3-65-68</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Savinova AR, Gataullin IG, Shakirov RR, Yarovaya EYu. Computer program for the realization of the algorithm of risk of relapse of ovarian neoplasm. Certificate of the State Registration of the Computer program № 2017619452 from 24.08.2017;1–12. (In Russ.). [Савинова А.Р., Гатауллин И.Г., Шакиров Р.Р., Яровая Е.Ю. Программа для реализации алгоритма оценки индивидуального риска рецидивирования рака яичников. Свидетельство о государственной регистрации программы для ЭВМ № 2017619452 от 24.08.2017 г.;1–12].</mixed-citation></ref></ref-list></back></article>
